BETRF:OTC-BetterLife Pharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.103

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

6.70K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

-0.51 (-0.56%)

USD 34.50B
UCBJF UCB SA

N/A

USD 34.43B
ARGNF argenx SE

N/A

USD 31.41B
GNMSF Genmab A/S

-7.90 (-2.95%)

USD 17.62B
ZLDPF Zealand Pharma A/S

+5.95 (+4.55%)

USD 9.35B
IVBIY IVBIY

N/A

USD 8.92B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.30B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.29B
WXXWY WuXi Biologics (Cayman) Inc

-0.04 (-1.37%)

USD 5.87B
WXIBF WuXi Biologics

N/A

USD 5.87B

ETFs Containing BETRF

XSOE WisdomTree Emerging Marke.. 1.72 % 0.32 %

+0.07 (+0.42%)

N/A
SPEM SPDR® Portfolio Emerging.. 1.43 % 0.12 %

+0.16 (+0.42%)

USD 9.24B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 114.58% 75% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 114.58% 75% C 87% B+
Trailing 12 Months  
Capital Gain 58.46% 72% C 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.46% 72% C 82% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -28.64% N/A N/A 8% B-
Dividend Return -28.64% N/A N/A 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.29% N/A N/A 52% F
Risk Adjusted Return -60.56% N/A N/A 12% F
Market Capitalization 0.01B 52% F 39% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.